At a glance
ClinicalIndex Comparison RecordPhase 2Active· 13 enrolled
Drug / intervention
Eribulindrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Pilot Phase 2 Study of Eribulin in Angiosarcoma and Epithelioid Hemangioendothelioma (EHE)
In Brief
A Phase 2 clinical trial evaluating Eribulin for Angiosarcoma and Epithelioid Hemangioendothelioma. Active but no longer recruiting, targeting 13 participants across 2 sites.
Detailed Summary
This research study is studying a drug as a possible treatment for Angiosarcoma or Epithelioid hemangioendothelioma (EHE). -The drug involved in this study is Eribulin
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAngiosarcoma, Epithelioid Hemangioendothelioma
CountriesUnited States
CollaboratorsEisai Inc.
Timeline
Phase 2ActiveOverdue
201820192020202120222023202420252026
First PostedNov 2017
Enrollment StartJan 2018
Primary CompletionJul 2023
Study CompletionFeb 2026
TodayJul 2026
First PostedNov 6, 2017
Enrollment StartJan 18, 2018
Primary CompletionJul 21, 2023
Study CompletionFeb 1, 2026
TodayJul 2, 2026
Enrollment to primary: 5.5 yearsPosted 8.7 years ago
Interventions
Eribulindrug
It may work by preventing the cancer cells from dividing and eventually cause the tumor cells to die